164 related articles for article (PubMed ID: 23408016)
1. Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma.
Kao SC; van Zandwijk N; Corte P; Clarke C; Clarke S; Vardy J
Support Care Cancer; 2013 Jul; 21(7):1879-84. PubMed ID: 23408016
[TBL] [Abstract][Full Text] [Related]
2. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
Warby A; Dhillon HM; Kao S; Vardy JL
Support Care Cancer; 2019 Sep; 27(9):3509-3519. PubMed ID: 30684047
[TBL] [Abstract][Full Text] [Related]
3. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
[TBL] [Abstract][Full Text] [Related]
4. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
[TBL] [Abstract][Full Text] [Related]
5. External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
Kataoka Y; Yamamoto Y; Otsuki T; Kaku S; Maehashi-Wada N; Fukuma S; Hirabayashi M; Nakano T; Fukuhara S
Lung Cancer; 2017 Nov; 113():88-92. PubMed ID: 29110856
[TBL] [Abstract][Full Text] [Related]
6. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
7. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
[TBL] [Abstract][Full Text] [Related]
8. Management of Malignant Pleural Mesothelioma in the Elderly Population.
Verma V; Wegner RE; Ludmir EB; Hasan S; Colonias A; Grover S; Friedberg JS; Simone CB
Ann Surg Oncol; 2019 Aug; 26(8):2357-2366. PubMed ID: 31011908
[TBL] [Abstract][Full Text] [Related]
9. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
Hasani A; Alvarez JM; Wyatt JM; Bydder S; Millward M; Byrne M; Musk AW; Nowak AK
J Thorac Oncol; 2009 Aug; 4(8):1010-6. PubMed ID: 19546819
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.
Larose F; Quigley N; Lacasse Y; Martel S; Lang-Lazdunski L
Lung Cancer; 2021 Jun; 156():151-156. PubMed ID: 33962765
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
12. Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Grover S; Friedberg JS; Simone CB
J Thorac Cardiovasc Surg; 2019 Feb; 157(2):758-766.e1. PubMed ID: 30454981
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete remission of malignant pleural mesothelioma after combined modality treatment: a case report.
Moubax K; Van Damme V; Nafteux P; Van den Heuvel M; Verbeken E; Lievens Y; Nackaerts K
Acta Clin Belg; 2013; 68(5):386-8. PubMed ID: 24579249
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report.
Hisakane K; Ohmatsu H; Umemura S; Kirita K; Matsumoto S; Yoh K; Niho S; Goto K
J Nippon Med Sch; 2017; 84(5):231-236. PubMed ID: 29142184
[TBL] [Abstract][Full Text] [Related]
15. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma.
Cho BC; Feld R; Leighl N; Opitz I; Anraku M; Tsao MS; Hwang DM; Hope A; de Perrot M
J Thorac Oncol; 2014 Mar; 9(3):397-402. PubMed ID: 24445595
[TBL] [Abstract][Full Text] [Related]
16. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
Katzman D; Sterman DH
Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
[TBL] [Abstract][Full Text] [Related]
17. Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
Frick AE; Nackaerts K; Moons J; Lievens Y; Verbeken E; Lambrecht M; Coolen J; Dooms C; Vansteenkiste J; De Leyn P; Nafteux P
Eur J Cardiothorac Surg; 2019 May; 55(5):934-941. PubMed ID: 30535191
[TBL] [Abstract][Full Text] [Related]
18. Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia.
Kao SC; Clarke S; Vardy J; Corte P; Clarke C; van Zandwijk N
Intern Med J; 2013 Apr; 43(4):402-10. PubMed ID: 22909129
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
20. How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
Sharkey AJ; O'Byrne KJ; Nakas A; Tenconi S; Fennell DA; Waller DA
Lung Cancer; 2016 Oct; 100():5-13. PubMed ID: 27597274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
